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Abstract: 
Background & Aims: Use of direct-acting oral anticoagulants (DOACs) is increasing, 
but little is known about the associated risks in patients undergoing colonoscopy with 
polypectomy. We aimed to determine the risk of post-polypectomy complications in 
patients prescribed DOACs. 
Methods: We performed a retrospective analysis using the Clinformatics Data Mart 
Database (a de-identified administrative database from a large national insurance 
provider) to identify adults who underwent colonoscopy with polypectomy or endoscopic 
mucosal resection (EMR) from January 1, 2011, through December 31, 2015. We 
collected data from 11,504 patients prescribed antithrombotic agents (1590 DOAC, 3471 
warfarin, and 6443 clopidogrel) and 599,983 patients not prescribed antithrombotics of 
interest (controls). We compared 30-day post-polypectomy complications, including 
gastrointestinal bleeding (GIB), cerebrovascular accident (CVA), myocardial infarction 
(MI), and hospital admissions, of patients prescribed DOACs, warfarin, or clopidogrel vs 
controls. 
Results: Post-polypectomy complications were uncommon but occurred in a 
significantly higher proportion of patients receiving any antithrombotic vs controls 
(P<0.001). The percentage of patients in the DOAC group with GIB was 0.63% (95% CI, 
0.3%–1.2%) vs 0.2% (95% CI, 0.2%–0.3%) in controls. The percentage of patients with 
CVA in the DOAC group was 0.06% (95% CI, 0.01%–0.35%) vs 0.04% (95% CI, 
0.04%–0.05%) in controls. After we adjusted for bridge anticoagulation, EMR, Charlson 
comorbidity index (CCI), and CHADS2 (congestive heart failure, hypertension, age over 
75, diabetes, stroke [double weight]) score, patients prescribed DOACs no longer had a 
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statistically significant increase in the odds of GIB (odds ratio [OR], 0.90; 95% CI, 0.44–
1.85), CVA (OR, 0.45; 95% CI, 0.06–3.28), MI (OR, 1.07; 95% CI, 0.14–7.72), or 
hospital admission (OR, 0.86; 95% CI, 0.64–1.16). Clopidogrel, warfarin, bridge 
anticoagulation, higher CHADS2, CCI, and EMR were associated with increased odds of 
complications. 
Conclusion: In our retrospective analysis of a large national dataset, we found that 
patients prescribed DOACs did not have significantly increased adjusted odds of post-
polypectomy GIB, MI, CVA, or hospital admission. Bridge anticoagulation, higher 
CHADS2 score, CCI, and EMR were risk factors for GIB, MI, CVA, and hospital 
admissions. Studies are needed to determine the optimal peri-procedural dose for high-
risk patients.  
 
KEY WORDS: endoscopy, anticoagulation, colon polyps, outcomes 
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Introduction 
Colonoscopy with polypectomy has been shown to be an effective screening 
intervention, with associated decreases in colorectal cancer (CRC) incidence by up to 
90% and death by up to 50%, in comparison to historical controls.1-3 It is considered a 
safe, minimally invasive outpatient procedure, with an estimated perforation risk of 
0.93%4 and bleeding risk ranging from 0.1% to 10%3. A confounding factor in the risk of 
post-polypectomy bleeding is the use of antithrombotic agents such as warfarin, 
clopidogrel and direct-acting oral anticoagulants (DOACs)5.  
DOACs, including newer anticoagulation agents such as rivaroxaban, apixaban, 
dabigatran, and edoxaban, are approved for the prevention of cerebrovascular accidents 
(CVA) in patients with a history of atrial fibrillation (AF)6 and venous thrombotic 
embolism (VTE)7. Over the past decade, these agents have been increasingly prescribed, 
and account for over half of all new anticoagulation prescriptions in patients with AF8. 
Compared to warfarin, DOACs have been found to reduce the risk of CVA by 19% but 
increase the risk of all-cause gastrointestinal bleeding (GIB) by 25%9.  Individually, 
apixaban is associated with a lower risk of GIB compared to rivaroxaban or dabigatran10. 
Current guidelines recommend that DOACs and other antithrombotic medications be held 
prior to polypectomy, with or without bridge therapy5. However, more recent literature 
suggests that DOACs may be safer than warfarin in terms for post-endoscopic bleeding11. 
The risk of procedure-related complications associated with DOACs in patients 
who undergo colonoscopy with polypectomy remains poorly understood. We 
hypothesized that patients prescribed DOACs who undergo polypectomy do not have a 
significantly higher risk of GIB compared to patients on no anticoagulation or patients on 
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other forms of antithrombotics. We aimed to evaluate the risk of complications following 
polypectomy in patients prescribed DOACs. 
 
Methods: 
Data Source:  
 We queried the Clinformatics Data Mart Database to identify adult patients with 
an outpatient encounter for colonoscopy with polypectomy or endoscopic mucosal 
resection (EMR) from January 1, 2011, to December 31, 2015. The Clinformatics Data 
Mart Database (OptumInsight, Eden Prairie, MN) is a de-identified database that contains 
inpatient, outpatient, and pharmacy data on 12-14 million individuals annually enrolled in 
a large commercial insurance plan and Medicare Advantage. We used International 
Classification of Diseases codes, 9th and 10th revisions (ICD9, ICD10), Current 
Procedural Terminology (CPT) codes, and pharmacy details. 
 
Cohort Definition: 
We identified any polypectomies performed on adult patients using specific CPT 
codes (44389, 44392, 44394, 44403, 44404, 45380, 45381, 45384, 45385 or 45390) in 
conjunction with specific ICD9 or ICD10 codes for colon or rectal polyps (Supplemental 
Table 1). We considered a procedure to be an EMR if the encounter included a CPT code 
for a snare polypectomy (44394, 45385) along with a CPT code for submucosal injection 
(44404, 45381) or if the encounter included a CPT code for EMR (45390, 44403). We 
excluded patients with coagulopathy and renal disease (Supplemental Table 2) as DOAC 
usage is contraindicated in these patients. 
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Antithrombotic use:  
We compared colonoscopy with polypectomy patients prescribed antithrombotics 
to a control group of patients who had not been prescribed any antithrombotics of 
interest. We identified patients with an active prescription for any DOAC, clopidogrel, 
and warfarin using the corresponding National Drug Code (NDC). We did not identify 
aspirin or non-steroidal anti-inflammatory drug (NSAID) use, as we did not have access 
to over-the-counter medication information.  
Active prescriptions were defined as those with an initiation date within 90 days 
prior to the procedure date and continuation after the procedure, indicated by pharmacy 
refills of the same antithrombotic medication within 90 days after the procedure with less 
than a one-week gap between the expected refill date and the actual refill date. We 
assumed that the exact peri-procedural management of the antithrombotic medications 
was done according to current society guidelines5. We grouped patients according to their 
antithrombotic prescriptions into DOAC, clopidogrel, or warfarin categories. We 
identified any patients who were on peri-procedure bridge anticoagulation, defined by 
prescription of enoxaparin, dalteparin, or fondaparinux within 14 days prior to the 
colonoscopy. We excluded patients on two or more combinations of DOAC, clopidogrel 
or warfarin due to the small size of this cohort.  
 
Primary and Secondary Outcomes:  
We analyzed clinically significant post-polypectomy GIB as defined by an 
inpatient encounter for GIB within 30 days of colonoscopy as our primary outcome of 
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interest (Supplemental Table 2b). Our secondary outcomes included inpatient encounters 
for CVA, VTE, myocardial infarction (MI), and any hospital admission within 30 days of 
index polypectomy.  
 
Covariates of Interest: 
We obtained the demographic information of each patient including age, gender, 
race, procedure type, and the date of polypectomy. Comorbidities of interest, as defined 
by specific ICD9 and ICD10 codes prior to polypectomy, included any history of GIB, 
MI, congestive heart failure, peripheral vascular disease (PAD), CVA, dementia, chronic 
pulmonary disease, rheumatic disease, peptic ulcer disease, liver disease, diabetes, 
hemiplegia, renal disease, malignancy, AIDS/HIV, coagulopathy, AF, VTE, and 
hypertension (Supplemental Table 2a). We calculated a Charlson comorbidity index 
(CCI)12 for each patient and a CHADS2 (congestive heart failure, hypertension, age over 
75, diabetes, stroke [double weight]) and CHA2D2VASc (congestive heart failure, 
hypertension, age over 75 [double weight], diabetes, stroke [double weight], age 65-74, 
sex [female]) score for each patient with AF13  
 
Statistical Analysis:  
We summarized the data as means, standard deviations (SD), medians, 
interquartile ranges (IQR), and proportions. We compared categorical variables using the 
chi-squared test and continuous variables with the ANOVA test and the Kruskal-Wallis 
test. We performed multivariate logistic regressions to assess the risk for post-
polypectomy GIB, CVA, MI, and admissions for each type of antithrombotic compared 
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to control. We chose the covariates for our multivariate model based on clinically 
relevant risk factors for post-polypectomy bleeding and thrombotic outcomes. In our 
multivariate model, we adjusted for CCI, use of bridge anticoagulation, and procedure 
type (EMR versus polypectomy) based on clinically relevant factors related to post-
polypectomy bleeding risk14, 15. We also adjusted for the CHADS2 score, as this is a 
validated measure of CVA risk in patients with AF. This analysis was performed for each 
antithrombotic subgroup (DOAC, warfarin, and clopidogrel). A multivariate analysis was 
not performed for VTE due to the small number of events.  
  
Sensitivity Analysis: 
 In order to assess how risk factors for post-polypectomy bleeding complications 
may differ from post-polypectomy thrombotic complications, we performed additional 
analyses by including the history of GIB in our multivariate regressions. Considering AF 
is a common indication for antithrombotic usage, we performed our multivariate 
regression analysis on an AF-only subgroup. We also assessed the impact of the new risk 
stratification system, the CHA2DS2VASc score, in our model. 
 
Results: 
Patient Characteristics: 
We identified 746,492 patients who underwent colonoscopy with polypectomy 
and excluded 65,568 patients with renal disease and coagulopathy and 37 patients with 
active prescriptions for two or more anticoagulants of interest (Figure 1). Our final cohort 
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consisted of 1590 patients prescribed any DOAC, 3471 patients prescribed warfarin, and 
6443 patients prescribed clopidogrel and 599,983 control patients. 
 Patient demographics and characteristics are summarized in Tables 1 and 2. 
Patients prescribed antithrombotics were more often male and older than the control 
group (P<.001) (Table 1). Patients prescribed antithrombotics had a higher mean CCI 
(1.7, SD 2.1 [DOACs]; 1.8, SD 1.7 [warfarin]; 1.9, SD 1.7 [clopidogrel]) compared to the 
control group (0.8, SD 0.5) (P<.001) (Table 2). Patients with a history of AF represented 
83.8% of patients in the DOAC group and 64.3% of patients in the warfarin group 
compared to 1.9% of patients in the control group (P<.001). A higher proportion of 
patients in the antithrombotic groups also had a history of CVA, VTE, PAD, MI, and 
GIB compared to the control group (P <.001). Bridge anticoagulation therapy was most 
commonly used with patients prescribed warfarin (11.4%) compared to patients 
prescribed DOACs (1.6%), and no patients in the control group (0%) (P<.001).  
 
Outcomes Analysis: 
Patients prescribed any antithrombotic medications had higher rates of 
complications compared to controls (P<.001) (Figure 2), though the overall occurrence of 
complications after polypectomy remained low. 
Gastrointestinal bleeding 
Post-polypectomy GIBs occurred in 10 patients in the DOAC group (rate 0.6%, 
95% CI 0.3%-1.2%), 43 patients in the warfarin group (rate 1.2%, 95% CI 0.9%-1.7%) 
and 59 patients in the clopidogrel group (rate 0.9%, 95% CI 0.7%-1.2%). This compares 
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to 1430 patients with GIBs in the control group (rate 0.2%, 95% CI 0.2% - 0.3%) (Figure 
2). There was no significant difference in median days to event (P=.35). 
Hospital Admissions 
 In total, there were 54 admissions in the DOAC group (rate 3.4%, 95% CI 2.6%-
4.4%) compared to 143 in the warfarin group, (rate 4.1%, 95% CI 3.7%-5.0%), 217 in the 
clopidogrel group (rate 3.4%, 95% 3.0% - 3.9%) and 10,782 in the control group (rate 
1.8%, 95% CI 1.7%- 1.8%) (P<.001) (Figure 2). The median days to admission was 7 
days (IQR 3-18) for patients on DOACs, 10 days (IQR 3-21) for patients on warfarin, 13 
days (IQR 5-21) for patients on clopidogrel, and 13 days (IQR 4-21) for control patients 
(P =.05). The most common diagnosis associated with an admission for the entire cohort 
was post-hemorrhagic anemia (ICD-9 285.1, 14.5%).  
Cerebrovascular accidents 
 There was only one admission for CVA in the DOAC group (0.06%, 95% CI 
0.01% - 0.35%). There were 13 admissions for CVA in the warfarin group (0.4%, 95% 
CI 0.2% - 0.6%), 18 admissions in the clopidogrel group (0.3%, 95% CI 0.2% - 0.5%), 
and 238 patients admitted for CVA (rate 0.04%, 95% CI 0.04% - 0.05%) in the control 
group (Figure 2). The median days to CVA was 10 days in the DOAC group, 22 days 
(IQR 6-22) in the clopidogrel group, 13 days (IQR 5-18) in the warfarin group, and 13 
days (IQR 5 - 21) for the control group (P=.05).  
Other complications 
 There were two admissions for MI in the DOAC group (rate 0.13%, 95% CI 
0.04% - 0.46%), 5 in the warfarin group (rate 0.1%, 95% CI 0.1% - 0.3%) and 20 in the 
clopidogrel group (rate 0.3%, 95% CI 0.2% - 0.5%) (Figure 2). In contrast, there were 
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179 patients admitted for MI in the control group (rate 0.03%, 95% CI 0.03% - 0.03%). 
There was no significant difference in the days to event between the groups, P=.33. There 
were no admissions for VTE in the DOAC or warfarin cohort, only one in the clopidogrel 
cohort, and four in the control group. 
 
Multivariate Analysis 
After adjusting for bridge anticoagulation, procedure type, CCI, and CHADS2 
score, we found that patients with an active DOAC prescription did not have a 
statistically significant increase in the odds of GIB (OR 0.90, 95% CI 0.44-1.85), CVA 
(OR 0.45, 95% CI 0.06-3.38), MI (OR 1.07, 95% CI 0.14-7.72), or admissions (OR 0.86, 
95% CI 0.64 to 1.16) compared to control (Figure 3, Table 3). Odds of GIB, CVA, and 
readmission remained elevated with both warfarin and clopidogrel prescriptions. 
Warfarin was associated with an OR of 1.90 for GIB (95% CI 1.28-2.83), an OR of 2.57 
for CVA (95% CI 1.28-5.17), an OR of 1.07 for MI (95% CI 0.63-5.80), and an OR of 
1.07 for admissions (95% CI 0.87-1.31). Clopidogrel was associated with the highest 
odds of GIB (OR 2.84, 95% CI 2.16-3.73), CVA (OR 4.04, 95% CI 2.42-6.74), MI (OR 
5.79, 95% CI 3.49-9.62), and admissions (OR 1.33, 95% CI 1.15-1.54) compared to the 
other antithrombotics.  
EMR procedure type, bridge anticoagulation, higher CCI, and CHADS2 score 
were also found to be independent risk factors for GIB, CVA, MI, and admissions (Table 
3). EMR was associated with the highest odds of GIB (OR 4.96, 95% CI 4.36-5.64), and 
admissions (OR 5.18, 95% CI 4.93-5.44). Bridge anticoagulation use was also an 
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independent risk factor for GIB (OR 3.29, 95% CI 1.68-6.44) and admissions (OR 1.67, 
95% CI 1.06-2.65) 
 
Sensitivity Analysis:  
Active DOAC prescriptions were not associated with a significant increase in the 
odds of GIB, CVA, MI, or admissions (Supplemental Table 3) when the model was 
adjusted for a history of GIB, though a history of GIB was associated with an increase in 
the odds of post-polypectomy GIB (OR 1.42, 95% CI 1.23-1.64) and admissions (OR 
1.46, 95% CI 1.38-1.54). We did not find the use of CHA2DS2VASc score to affect the 
findings of the multivariate model (Supplemental Table 4A). In the AF subgroup, no 
antithrombotics were associated with statistically significant increased odds of GIB, 
CVA, MI, or admissions (Supplemental Table 4B). 
 
Discussion: 
Our findings provide necessary data for the understanding of adverse events in 
patients prescribed DOACs who undergo colonoscopy with polypectomy. The overall 
rates of complications in polypectomy or EMR patients were low, but higher in patients 
prescribed any antithrombotics compared to patients in the control group (P< 0.001). 
After adjusting for bridge anticoagulation use, patient comorbidities, and procedure type, 
patients prescribed DOACs did not have a statistically significant increase in the odds of 
GIB, CVA, MI, or admissions as compared to the control group. Clopidogrel and 
warfarin remained associated with an increased risk of post-polypectomy bleeding, CVA, 
MI, and admissions compared to the control group. 
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Our study highlights the relative safety of DOACs compared to warfarin and 
clopidogrel. We found that patients prescribed warfarin and clopidogrel had an increased 
risk for GIB, CVA, MI, and admissions, although the increase in the odds of admissions 
and MI in the warfarin group was not statistically significant. These findings were seen 
throughout most of our sensitivity analyses with the exception of the AF-only sub-group; 
however, we note that the AF-only cohort consisted of 11,322 patients and thus is likely 
underpowered. A 2012 study, which compared patients on dabigatran to patients on 
warfarin, found similar risks of peri-procedural bleeding and thromboembolic events 
between the two medications16. More recent studies have suggested DOACs may have a 
lower risk of post-polypectomy bleeding compared to warfarin11, 17, 18 in line with our 
study findings. Similarly, clopidogrel use has also been associated with an increased risk 
of post-polypectomy bleeding19, 20. 
Our analyzed cohort is one of the largest studied antithrombotic groups who 
underwent colonoscopy with polypectomy and includes both men and women with a 
mean age of 61.2 years (SD 10.7) and a mean CCI of 0.87 (SD 1.34). Such a robust 
dataset allowed us to perform risk stratification to facilitate guidance on the highest risk 
polypectomy group. Providers should still use caution in managing antithrombotics in 
older patients with more comorbid conditions, as we found increasing CCI and CHADS2 
score to be additional risk factors for complications in our multivariate regression model 
(Table 3).  
The use of bridge anticoagulation has been linked to a higher risk of GIB21. We 
also found bridge anticoagulation to be an independent risk factor for GIB and 30-day 
admissions. Other risk factors for post-polypectomy bleeding that had been previously 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 15 
identified include larger, complex polyps15, and a right-sided location22. While we could 
not identify the exact location or characteristic of the polyp, we found EMR is an 
independent risk factor for all complications with a five-fold increase in the odds of GIB 
and admissions and a two-fold increase in the odds of CVA and MI. 
Our study is not without limitations. We recognize that since this study is a 
retrospective analysis of administrative data there may have been information bias 
present. We minimized misclassification errors by including only polypectomies for 
benign polyps by associating the appropriate CPT codes for the polypectomy procedure 
with the ICD9 or ICD10 codes for benign polyps. We applied strict active prescription 
criteria by requiring both an active prescription at the time of procedure as well as a 
medication refill within 90 days after the procedure and no more than a 7-day gap 
between refills. However, it is possible that patients could have been instructed to 
continue or stop anticoagulation in accordance with current guidelines. Furthermore, peri-
procedural medication management may have differed between the antithrombotic 
groups. In addition, as only prescription medication information was available, we could 
not reliably identify patients on over-the-counter aspirin and NSAIDs. Patients may have 
been on aspirin or NSAIDs in combination with an antithrombotic of interest. 
Importantly, aspirin and NSAID use have been shown to be safe in polypectomy23 and 
are not routinely held prior to procedures. Therefore, we do not believe the inability to 
identify usage significantly impacts our findings.  
In our analysis, we adjusted for multiple patient and procedure-related factors, 
however, there may be unmeasured confounders contributing to our findings. We also 
note that there is a difference in cohort size between the 3 antithrombotic groups of 
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interest. We performed post-hoc power analyses to assess the strength of our findings, as 
we recognize that patients on warfarin and clopidogrel were more represented in the 
antithrombotic cohort (i.e. 1590 patients prescribed DOACs compared to 3471 prescribed 
warfarin and 6443 prescribed clopidogrel). Despite the smaller DOAC cohort, post-hoc 
power analyses reveal that we achieved a power of 82% for GIB and 98.1% for 
admissions outcomes using the effect sizes observed and a significance level of 0.05. The 
power was less than 80% for CVA and MI. Larger studies on post-polypectomy CVA 
and MI complications in patients on DOACS may provide stronger conclusions. 
 
Conclusion:   
Our study found that active DOAC prescriptions were not associated with 
significantly increased adjusted odds of GI bleeding, CVA, MI or 30-day admissions 
after polypectomy compared to patients in the control group after adjusting for procedure 
complexity, bridge anticoagulation use, CHADS2 score, and CCI. Patients with a higher 
CHADS2 score, comorbidity index, bridge anticoagulation use, or undergoing EMR may 
be at higher risk. Further studies on high-risk patients, optimal peri-procedural dosing, 
and bleeding prophylaxis are needed.
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Tables: 
Table 1. Patient demographics. All categories are statistically significant at p<0.001 compared to controls. 
 
  
Control  
N=599,983 
DOAC  
N=1590 
Warfarin  
N=3471 
Clopidogrel 
N=6443 
Age, Mean (SD) 60.6 (10.7) 68.6 (8.6) 68.9 (9.2) 67.3 (8.4) 
Gender, n (%)     
Male 305,723 (51.0%) 1,052 (66.2%) 2,192 (63.2%) 4,400 (68.3%) 
Female 294,235 (49.0%) 538 (33.8%) 1,279 (36.9%) 2,024 (31.7%) 
Race, n (%)     
White 434,973 (75.9%) 1,264 (83.4%) 2,621 (79.6%) 4,594 (74.9%) 
Black 54,527 (9.5%) 100 (6.6%) 289 (8.9%) 666 (10.9%) 
Asian 20,033 (3.5%) 42 (2.8%) 75 (2.3%) 263 (4.3%) 
Hispanic 43,773 (7.6%) 60 4.0%) 183 (5.6%) 424 (6.9%) 
Unknown 19,822 (3.5%) 50 (3.3%) 124 (3.8%) 190 (3.1%) 
SD, Standard Deviation  
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Table 2. Patient clinical characteristics. All categories are statistically significant at p<0.001 compared controls. 
 
Control  DOAC  Warfarin  Clopidogrel 
 N=599,983 N=1590 N=3471 N=6443 
CCI Score, mean (SD) 0.8 (0.5) 1.7 (2.1) 1.8 (1.7) 1.9 (1.7) 
Comorbidities     
AF, n (%) 11,322 (1.9%) 1,332 (83.8%) 2,231 (64.3%) 503 (7.8%) 
CVA, n (%) 33,094 (5.5%) 347 (21.8%) 704 (20.3%) 2,162 (33.6%) 
VTE, n (%) 189 (0.03%) 19 (1.2%) 84 (2.4%) 16 (0.3%) 
MI, n (%) 8257 (1.4%) 137 (8.6%) 281 (8.1%) 1504 (23.3%) 
PAD, n (%) 37,099 (6.2%) 1333 (20.9%) 750 (21.6%) 2,023 (31.4%) 
GIB, n (%) 59,011 (9.8%) 261 (16.4%) 497 (14.3%) 933 (14.5%) 
CHADS2 Score, mean 
(SD) 0.03 (0.33) 1.9 (1.4) 1.6 (1.6) 0.2 (0.8) 
CHA2DS2VASc, mean 
(SD) 
0.06 (0.5) 3.0 (2.1) 2.5 (2.3) 0.3 (1.2) 
Bridge Anticoagulation, 
n (%) 
0 (0%) 26 (1.6%) 394 (11.4%) 21 (0.3%) 
EMR, n (%) 28,323 (4.7%) 91 (5.7%) 208 (6.0%) 6351 (5.5%) 
CCI, Charlson comorbidity index; EMR, endoscopic mucosal resection; SD, standard deviation;  
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Table 3. Results of the complete multivariate regression model. 
 
CCI, Charlson comorbidity index; CI, confidence interval; CVA, cerebrovascular accident; DOAC, direct-acting oral anticoagulant; 
EMR, endoscopic mucosal resection; GIB, gastrointestinal bleeding; OR, odds ratio; 
 
  
OR (95% CI) GIB CVA MI Any Admission 
Antithrombotic     
DOAC 0.90 (0.44-1.85) 0.45 (0.06-3.38) 1.07 (0.14-7.72) 0.86 (0.64-1.16) 
Warfarin 1.90 (1.28-2.83) 2.57 (1.28-5.17) 1.91 (0.63-5.80) 1.07 (0.87-1.31) 
Clopidogrel 2.84 (2.16-3.73) 4.04 (2.42-6.74) 6.28 (3.84-10.29) 1.33 (1.15-1.54) 
CCI 1.16 (1.12-1.20) 1.30 (1.23-1.37) 1.27 (1.87-4.30) 1.22 (1.21-1.24) 
CHADS2 Score 1.34 (1.25-1.43) 1.49 (1.32-1.67) 1.16 (0.97-1.39) 1.26 (1.22-1.30) 
EMR 4.96 (4.36-5.64) 2.00 (1.32-3.03) 2.84 (1.87-4.30) 5.18 (4.93-5.44) 
Bridge anticoagulation 3.29 (1.68-6.44) 2.64 (0.74-9.44) 4.36 (0.85-22.43) 1.67 (1.06-2.65) 
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Figure Legends: 
 
 
Figure 1. Study flow diagram. 
 
Figure 2. 30-day complications rates after polypectomy. P<0.001 for all outcomes. 
 
Figure 3. The adjusted odds ratio of 30-day complications after polypectomy by 
antithrombotic type with no antithrombotic or aspirin as reference. The multivariate 
model is adjusted for EMR procedure, CCI and CHADS2 score. The results of the full 
multivariate model are summarized in Table 3. 
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What You Need to Know 
 
Background: The risk of post-polypectomy complications in patients on DOACs is 
poorly understood. We compared post-polypectomy outcomes of patients 
prescribed DOACs, warfarin, clopidogrel to control patients with no antithrombotic 
prescriptions. 
 
Findings: Patients prescribed DOACs had low but increased rates of complications 
compared to controls, but this was non-significant on multivariable regression. 
Other risk factors include patient comorbidities, bridge anticoagulation, and EMRs. 
 
Implications for patient care: Patients prescribed DOACs do not have increased 
adjusted odds of post-polypectomy complications. Providers should use caution in 
managing patients with bridge anticoagulation, higher comorbidities, and 
undergoing EMRs.  
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Supplemental Materials 
 
Table 1. Procedure codes of interest  
Procedure type CPT, ICD9 and 
ICD10 codes 
Colonoscopy thru stoma 
Biopsy 44389 
Hot biopsy 44392 
Snare 44394 
EMR 44403 
Submucosal Injection 44404 
Colonoscopy 
Biopsy 45380 
Submucosal Injection 45381 
Hot Biopsy 45384 
Snare 45385 
EMR 45390 
Colon polyp  211.3, K63.5, D12.0-
D12.7 
Rectal polyp  211.4, D12.8 
CPT, current procedural terminology; EMR, endoscopic mucosal resection; ICD9, 
international classification of diseases codes, 9th revision; ICD10, international 
classification of diseases codes, 10th revision; 
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Table 2. ICD9 and ICD10 codes for comorbidities and complications of interest 
 
A) Comorbidities of interest: 
 ICD9 ICD10 
MI 410.x, 412.x I21.x, I22.x, 125.2 
Congestive heart failure 398.91, 402.01, 402.11, 
402.91, 404.01, 404.03, 
404.11, 404.13, 404.91, 
404.93, 425.4-425.9, 428.x 
I09.9, I11.0, I13.0, I13.2, 
I25.5, I42.0, I42.5-I42.9, 
I43.x, I50.x, P29.0 
PAD O93.0, 437.4, 440.x, 441.x, 
443.1-443.9, 47.1, 557.1, 
557.9 V43.4 
I70.x, I71.x, I73.1, I73.8, 
I73.9, I77.1, I79.0, I79.2, 
K55.1 K55.8, K55.9, Z95.8, 
Z95.9 
CVA 362.34, 430.x-438.x 
 
G45.x, G46.x, H34.0, I60.x-
I69.x 
Dementia 290.x, 294.1, 331.2 FOO.x-F03.x, F05.1, 
G30.x, G31.1 
Chronic pulmonary disease 416.8, 416.9, 490.x-505.x, 
506.4, 508.1, 508.8 
127.8, 127.9, J40.x-J47.x, 
J60.x-J67.x, J68.4, J70.1, 
J70.3 
Rheumatic disease 446.5, 710.0-710.4, 714.0- 
714.2, 714.8, 725.x 
M05.x, M06.x, M31.5, 
M32.x-M34.x, M35.1, 
M35.3, M36.0 
Peptic ulcer disease 531.x-534.x K25.x-K28.x 
Mild liver disease 070.22, 070.23, 070.32, 
070.33, 070.44, 070.54, 
070.6, 070.9, 570.x, 571.x, 
573.3, 573.4, 573.8, 573.9, 
V42.7 
B18.x, K70.0-K70.3, 
K70.9, K71.3-K71.5, 
K71.7, K73.x, K74.x, 
K76.0, K76.2-K76.4, 
K76.8, K76.9, Z94.4 
Diabetes without  
complications 
250.0-250.3, 250.8, 250.9 
 
E10.0, E10.1, E10.6, E10.8, 
E10.9, E11.0, E11.1, E11.6, 
E11.8, E11.9, E12.0, E12.1, 
E12.6, E12.8, E12.9, E13.0, 
E13.1, E13.6, E13.8, E13.9, 
E14.0, E14.1, E14.6, E14.8, 
E14.9 
Diabetes with complications 250.4-250.7 E10.2-E10.5, El0.7, E11.2-
Ell11.5, E11.7, E12.2-
E12.5, E12.7, E13.2- E13.5, 
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 E13.7, E14.2-E14.5, E14.7 
Hemiplegia 334.1, 342.x, 343.x, 344.0- 
344.6, 344.9 
 
G04.1, G11.4, G80.1, 
G80.2, G81.x, G82.x, 
G83.0-G83.4, G83.9 
Renal disease 403.01, 403.11, 403.91, 
404.02, 404.03, 404.12, 
404.13, 404.92, 404.93, 
582.x, 583.0-583.7, 585.x, 
586.x, 588.0, V42.0, V45.1, 
V56.x 
112.0, I113.1, N03.2-N03.7, 
N05.2- N05.7, N18.x, 
N19.x, N25.0, Z49.0- 
Z49.2, Z94.0, Z99.2 
Malignancy 140.x-172.x, 174.x-195.8, 
200.x-208.x, 238.6 
COO.x-C26.x, C30.x-
C34.x, C37.x- C41.x, 
C43.x, C45.x-C58.x, C60.x- 
C76.x, C81.x-C85.x, C88.x, 
C90.x-C97.x 
Moderate or severe liver 
disease 
456.0-456.2, 572.2-572.8 185.0, I185.9, I186.4, 
I198.2, K70.4, K71.1, 
K72.1, K72.9, K76.5, 
K76.6, K76.7 
Metastatic solid tumor 196.x-199.x 
 
C77.x-C80.x 
AIDS/HIV 042.x-044.x 
 
B20.x-B22.x, B24.x 
Coagulopathy 286.x, 287.1, 287.3- 287.5 D65-D68.x, D69.1, D69.3- 
D69.6 
Hypertension 401.x, 402.x, 403.x, 404.x, 
405.x 
I10.x, I11.x, I12.x, I13.x, 
I15.x 
Atrial fibrillation 427.31/427.32 I48.x 
GIB 456.0, 456.20, 530.7, 
530.82, 531.0x, 531.2x, 
531.4, 531.6x, 532.0x, 
532.2x, 532.4x, 532.6x, 
533.0x, 533.2x, 533.4x, 
533.6x, 534.0x, 534.2x, 
534.4x, 534.6x, 569.3, 
K92.2, K92.1, K29.01, 
K31.811, K57.x, K29.x, 
K25.0, K25.2, K25.4, 
K25.6, K62.5, D62, T81.0, 
K92.2 
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578.0, 578.1, 578.9, 998.1x 
CVA, cerebrovascular accident; GIB, gastrointestinal bleeding; ICD9, international 
classification of diseases codes, 9th revision; ICD10, international classification of 
diseases codes, 10th revision; MI, myocardial infarction; PAD, peripheral vascular 
disease;  
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B) Complications of interest 
 ICD9 ICD10 
GIB 456.0, 456.20, 530.7, 
530.82, 531.0x, 531.2x, 
531.4, 531.6x, 532.0x, 
532.2x, 532.4x, 532.6x, 
533.0x, 533.2x, 533.4x, 
533.6x, 534.0x, 534.2x, 
534.4x, 534.6x, 569.3, 
578.0, 578.1, 578.9, 998.1x 
K92.2, K92.1, K29.01, 
K31.811, K57.x, K29.x, 
K25.0, K25.2, K25.4, 
K25.6, K62.5, D62, T81.0, 
K92.2 
CVA 362.34, 430.x-438.x 
 
G45.x, G46.x, H34.0, I60.x-
I69.x 
MI 410.x, 412.x I21.x, I22.x, 125.2 
VTE 997.79, 415.11 T81.718A, T81.72XA, 
I26.90, I26.99, T80.0XXA, 
T81.718A, T81.72XA, 
T82.817A, T82.818A 
CVA, cerebrovascular accident; GIB, gastrointestinal bleeding; ICD9, international 
classification of diseases codes, 9th revision; ICD10, international classification of 
diseases codes, 10th revision; MI, myocardial infarction; VTE, venous thromboembolism 
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Table 3. Multivariate logistic regression model for post-procedural outcomes adjusted for 
GIB history in addition to antithrombotic use, bridge anticoagulation, CCI, CHADS2 
score and EMR use. 
 
CI, confidence interval; CCI, Charlson comorbidity index; CVA, cerebrovascular 
accident DOAC, direct-acting oral anticoagulant; EMR, endoscopic mucosal resection; 
GIB, gastrointestinal bleeding; OR, odds ratio; MI, myocardial infarction 
 
  
OR (95% CI) GIB CVA MI Any Admission 
Antithrombotic     
DOAC 0.89 (0.43-1.83) 0.44 (0.06-3.25) 1.03 (0.14-7.73) 0.86 (0.64-1.15) 
Warfarin 1.91 (1.28-2.84) 2.60 (1.30-5.22) 1.91 (0.63-5.80) 1.08 (0.88-1.32) 
Clopidogrel 2.82 (2.15-3.71) 4.02 (2.41-6.70) 6.29 (3.84-10.31) 1.32 (1.14-1.53) 
Bridge 
Anticoagulation 
3.31 (1.69-6.49) 2.65 (0.74-9.45) 4.35 (0.85-4.31) 1.68 (1.06-2.66) 
CCI 1.15 (1.11-1.19) 1.98 (1.31-3.00) 1.37 (1.29-1.45) 1.21 (1.20-1.22) 
CHADS2 Score 1.33 (1.24-1.43) 1.47 (1.31-1.66) 1.16 (0.97-1.39) 1.25 (1.22-1.29) 
EMR 1.42 (1.23-1.64) 1.29 (1.22-1.36) 2.84 (1.88-4.31) 5.13 (4.88-5.39) 
GIB history 1.42 (1.23-1.64) 1.38 (0.99-1.93) 0.93 (0.60-1.44) 1.46 (1.38-1.54) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 4. Sensitivity analysis. 
A) Adjusted odd of 30-day outcomes. Model is adjusted for procedure type, CCI and 
CHA2DS2VASc score. 
 
OR (95% CI) DOAC Warfarin Clopidogrel 
GIB 0.86 (0.42-1.76) 1.83 (1.23-2.73) 2.83 (2.16-3.72) 
CVA 0.44 (0.06-3.20) 2.54 (1.26-5.10) 4.06 (2.44-6.78) 
MI 0.98 (0.13-7.37) 1.83 (0.61-5.55) 6.25 (3.82-10.24) 
Admission 0.83 (0.62-1.12) 1.04 (0.85-1.27) 1.33 (1.15-1.54) 
CI, confidence interval; CVA, cerebrovascular accident DOAC, direct-acting oral 
anticoagulant; GIB, gastrointestinal bleeding; MI, myocardial infarction; OR, odds ratio 
 
B) Adjusted odd of 30-day outcomes for an atrial fibrillation only subgroup. Model is 
adjusted for procedure type, CCI, and CHADS2. 
 
OR (95% CI) DOAC Warfarin Clopidogrel 
GIB 0.51 (0.22-1.18) 0.93 (0.55-1.56) 1.02 (0.44-2.38) 
CVA 0.36 (0.05-2.66) 1.13 (0.45-2.83) 0.54 (0.07-4.09) 
MI 0.66 (0.08-5.21) 0.52 (0.09-3.16) 1.18 (0.15-9.38) 
Admission 0.65 (0.47-0.90) 0.72 (0.56-0.92) 0.77 (0.50-1.19) 
CI, confidence interval; CVA, cerebrovascular accident DOAC, direct-acting oral 
anticoagulant; GIB, gastrointestinal bleeding; MI, myocardial infarction; OR, odds ratio 
 
 
 
 
